These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36340458)

  • 21. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
    Abad A; Massutí B; Gallego J; Yuste AL; Manzano JL; Carrato A; Antón A; Marfa X; Diaz-Rubio E;
    Anticancer Drugs; 2004 Jun; 15(5):469-71. PubMed ID: 15166620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis.
    Sugimoto K; Sakamoto K; Ii Y; Amemiya K; Sugo H; Ito T; Munakata S; Takahashi M; Kojima Y; Tomiki Y; Sato K; Saiura A; Kawasaki S
    BMC Surg; 2021 Apr; 21(1):188. PubMed ID: 33836701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
    Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
    Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical administration of oxaliplatin for patients previously treated for refractory advanced or recurrent colorectal cancer].
    Takahari D; Tsuji Y; Sagawa T; Honda K; Sumiyoshi T; Yoshizaki N; Kuroiwa G; Kondo H
    Gan To Kagaku Ryoho; 2006 Jan; 33(1):49-54. PubMed ID: 16410698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test.
    Ochiai T; Nishimura K; Watanabe T; Kitajima M; Hashiguchi T; Nakatani A; Marusasa T; Muraki A; Nagaoka I; Futagawa S
    Exp Ther Med; 2010 Mar; 1(2):325-329. PubMed ID: 22993545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-124 Intensified Oxaliplatin-Based Chemotherapy by Targeting CAPN2 in Colorectal Cancer.
    Xie XQ; Wang MJ; Li Y; Lei LP; Wang N; Lv ZY; Chen KL; Zhou B; Ping J; Zhou ZG; Sun XF
    Mol Ther Oncolytics; 2020 Jun; 17():320-331. PubMed ID: 32382656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.
    Shimizu T; Abu Lila AS; Nishio M; Doi Y; Ando H; Ukawa M; Ishima Y; Ishida T
    Cancer Sci; 2017 Sep; 108(9):1864-1869. PubMed ID: 28643902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
    Del Re M; Omarini C; Diodati L; Palleschi M; Meattini I; Crucitta S; Lorenzini G; Isca C; Fontana A; Livi L; Piacentini F; Fogli S; De Giorgi U; Danesi R
    ESMO Open; 2021 Oct; 6(5):100231. PubMed ID: 34509802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study.
    Pasupuleti B; Gone V; Baddam R; Venisetty RK; Prasad OP
    Curr Drug Metab; 2020; 21(2):126-131. PubMed ID: 32067615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer.
    Yao Y; Zhao H; Sun Y; Lin F; Tang L; Chen P
    Tohoku J Exp Med; 2008 Jul; 215(3):267-78. PubMed ID: 18648187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ; Lin HY; Zhang Y; Chen WF
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.
    Furuta T; Iwaki T; Umemura K
    Br J Clin Pharmacol; 2010 Sep; 70(3):383-92. PubMed ID: 20716239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Silencing the
    Oh BY; Kim KH; Chung SS; Lee RA
    Ann Surg Treat Res; 2016 Dec; 91(6):273-277. PubMed ID: 27904848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of oxaliplatin in the therapy for advanced colorectal carcinoma].
    Nehls O; Porschen R; Gregor M; Klump B
    Z Gastroenterol; 2001 Dec; 39(12):1033-47. PubMed ID: 11753789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
    Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P
    J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats.
    Nishida K; Takeuchi K; Hosoda A; Sugano S; Morisaki E; Ohishi A; Nagasawa K
    Life Sci; 2018 Aug; 207():516-524. PubMed ID: 29981320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell.
    Zhang Y; Xu Z; Sun Y; Chi P; Lu X
    Onco Targets Ther; 2018; 11():809-821. PubMed ID: 29497313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.